Sarcopenia
Sarcopenia is loss of muscle mass and strength. In cancer it predicts worse chemotherapy side-effects, more surgical complications and shorter survival, and it can hide in people who look a normal weight or overweight.
Defined by low skeletal muscle mass (commonly the skeletal muscle index at the L3 vertebra on CT) with or without low strength or performance. Sarcopenic obesity, low muscle with high fat, carries the worst prognosis. Because muscle rather than total weight determines the clearance of many cytotoxics, sarcopenic patients dosed by body surface area are effectively overdosed. Automated CT segmentation makes opportunistic measurement feasible.
Pages like this
not linked directly; found by shared links- TechnologyCachexia-directed therapy (GDF-15 blockade)
Shares ROMANA 1 and ROMANA 2, Resistance training and protein for cachexia and sarcopenia, Cancer cachexia, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine.
- TechnologyNutrition support and cachexia management
Shares Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA), Resistance training and protein for cachexia and sarcopenia, Cancer cachexia, Oncology nutrition assessment and medical nutrition therapy.
- IdeaQualify a physical function endpoint so anti-wasting drugs can be approved
Shares ROMANA 1 and ROMANA 2, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Geriatric assessment, Cachexia, toxicity and the limits of the patient.
- PathwayCancer cachexia
Shares ROMANA 1 and ROMANA 2, Resistance training and protein for cachexia and sarcopenia, Cancer cachexia, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine.
- IdeaA dietitian in every gastrointestinal and head and neck tumour board
Shares Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA), Cancer cachexia, Oncology nutrition assessment and medical nutrition therapy, Geriatric assessment.
- TermNutrition impact symptoms
Shares Malnutrition screening tools (MUST, NRS-2002, MST, PG-SGA), Cancer cachexia, Oncology nutrition assessment and medical nutrition therapy, Cachexia, toxicity and the limits of the patient.
- TrialPonsegromab phase 2 in cancer cachexia
Shares Body composition (lean mass, fat mass, visceral fat), Cancer cachexia, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient.
- IdeaTreat cachexia as a disease: GDF-15 blockade plus anabolic and nutrition bundles
Shares Resistance training and protein for cachexia and sarcopenia, Cachexia pharmacotherapy: GDF-15 blockade, anamorelin, olanzapine, Cachexia, toxicity and the limits of the patient.